Vertex: Combined VX-809, Cystic-Fibrosis Drug Kalydeco Improved Lung Function
Wall Street Journal
Vertex Pharmaceuticals Inc. (VRTX) said interim results from an ongoing Phase 2 study showed the combined use of VX-809 and its cystic-fibrosis treatment Kalydeco improved lung function in adults who have two copies of the most common gene mutation.
A One-Two Punch Against Cystic Fibrosis, And Maybe Someday Other Diseases TooForbes
Vertex Cystic Fibrosis Combo Aids Breathing in PatientsBloomberg
Vertex Reports Interim Analysis Data From Phase 2 Study Of VX-809 And KalydecoNASDAQ
TheStreet.com -Xconomy -Reuters AlertNet
all 14 news articles »